CA2348893A1 - Process for preparing cross-bridged tetraaza macrocycles - Google Patents
Process for preparing cross-bridged tetraaza macrocycles Download PDFInfo
- Publication number
- CA2348893A1 CA2348893A1 CA002348893A CA2348893A CA2348893A1 CA 2348893 A1 CA2348893 A1 CA 2348893A1 CA 002348893 A CA002348893 A CA 002348893A CA 2348893 A CA2348893 A CA 2348893A CA 2348893 A1 CA2348893 A1 CA 2348893A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- ligand
- mixtures
- methyl
- tetraaza macrocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CCIC*CN(CCCCN(*)*)CCN(CC*)C*(C)=C Chemical compound CCIC*CN(CCCCN(*)*)CCN(CC*)C*(C)=C 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
- C07F13/005—Compounds without a metal-carbon linkage
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
- B01J31/1805—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
- B01J31/181—Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
- B01J31/1815—Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine
- B01J31/182—Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine comprising aliphatic or saturated rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/70—Complexes comprising metals of Group VII (VIIB) as the central metal
- B01J2531/72—Manganese
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/90—Catalytic systems characterized by the solvent or solvent system used
- B01J2531/96—Water
Abstract
The present invention relates to a process for preparing a cross-bridged tetraaza macrocyclic ligand having formula (I) wherein each R is independent ly C1-C8 linear or branched alkyl, -(CH2)xCO2M, and mixtures thereof; provided both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3; by contacting a d i- quaternary cis tetracycle precursor with hydrogen in the presence of a palladium catalyst in an aqueous solution having a pH of at least about 10 a t a temperature of about 40 ~C to about 100 ~C.
Description
WO 00!32601 PCT/US99/27316 PROCESS FOR PREPARING CROSS-BR)DGED
TETRAAZA MACROCYCLES
FIELD OF THE INVENTION
The present invention relates to an improved process for preparing cross-bridged tetraaza macrocycles, said macrocycles suitable as ligands for use in preparing transition metal complexes. The present invention provides a process which is well suited for use in industrial and other commercial preparations of the herein described crossed-bridged macrocycles.
BACKGROUND OF THE INVENTION
Tetraaza macrocyclics, for example, cyclam, have been prepared in numerous ways, however, there is a paucity of information relating to the preparation of cross-bridged tetraaza macrocyclics inter alia bis N-substituted tetraaza macrocyclics inter alia 5,12 dialkyl 1,5,8,12-tetraaza-bicyclo[6.6.2]hexadecanes which have recently found wide applicability as ligands especially in the area of transition metal catalysts inter alia bleach catalysts.
WO 98/39335 A1 "Improved Methods of Making Cross-Bridged Macropoly-cycles"
discloses a rational procedure for preparing cross bridged macropolycyclic ligands which is amenable to high yields necessary for industrial scale-up. However, the reductive ring cleavage step which results in bicyclo bridged-ring formation utilizes a borohydride reducing agent. This type of reducing agent can place constraints on the formulator. For example, the need to break up the amine/borohydride complex during work-up and the proper recovery and disposal of boron waste products adds cost to the process. Also, if excess borohydride is needed, this requires neutralization which involves the use of acid and the evolution of large quantities of hydrogen gas.
Therefore, a need exists for a highly quantitative, preferably catalytic, process for preparing cross-bridged macropolycyclic ligands which is adaptable to either continuous flow processes or batch preparations.
SUMMARY OF THE INVENTION
The present invention meets the aforementioned needs in that it has been surprisingly discovered that select bis N-substituted tetraaza macrocyclics can be converted to cross-bridged macropolycyclic ligands via catalytic hydrogenation.
A first aspect of the present invention relates to a process for preparing a tetraaza macrocyclic ligand having the formula:
(CHz~,~
~-N
(CH~~, R R {CHz~, ~N N
~ (~Hz~J
wherein each R is independently C,-C8 linear or branched alkyl, -(CH,)rCO~M, and mixtures thereof, preferably both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3; said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
(CHz~, R
~N H N
(CHz~, (CHz~, \ / 2X-~N H N
R J
/ ~ (CHz~,~
wherein X is an anion which provides charge neutrality, with from about 1 ppm of a transition metal hydrogenation catalyst at a pH of at least $ to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified.
All temperatures are in degrees Celsius (o C) unless otherwise specified. All documents cited are in relevant pan, incorporated herein by reference.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the catalytic hydrogenation of tetraaza macrocycles having the formula:
~(cH,~,~ /R
NI H IN
(CH~~, (CH=~, _ ~ / 2X
'-N H N
R
/ ~(CH.~,J
wherein the covalent bond between the N-substituted quaternary ring nitrogen and the bridging carbon is broken and a cross-bridged macrocyclic ligand having the formula:
(CH:~, ~--N i -~
(cH~~, R R (CH:~, ~N/ N
~ (~H~~J
is the resulting product.
In the above formula each R is independently C,-Ca linear or branched alkyl, -(CH,)rCO~M, and mixtures thereof, preferably both of the R units are not methyl; more preferably one R unit is methyl and the other R unit is selected from the group consisting of ethyl, propyl, butyl, pentyl, hexyl, and mixtures thereof of the methyl/alkyl R unit mixtures preferably one R is methyl and the other R is ethyl or propyl. A most preferred ligand consists of a unit wherein one R unit is methyl and the other R unit is ethyl. A preferred ligand is a macrocyclic ring wherein each R unit is ethyl. M is hydrogen or a salt forming cation, non-limiting examples of which are sodium, potassium, calcium, ammonium. When R is -(CH~)xCO~M the index x has the value from 1 to about 6, preferably x is 1. The index n defines the size of the macrocyclic ring. The index n has the value of from 0 to about 3. A preferred macrocyclic ring has one opposite set of n indices equal to 1 and the other set of n indices equal to 0 as in the general formula:
N N
R R
N N
wherein R is the same as defined herein above.
Preferred ligands according to the present invention comprise R unit pairs which are selected from the group consisting of methyl and ethyl, diethyl, methyl and propyl, ethyl and propyl, methyl and butyl. ethyl and butyl, and mixtures thereof.
The starting materials for the process of the present invention are tetraaza macrocyclic ligand precursors, or alternatively, bis-quaternary cis tetracycles, having the formula:
(CH:~, R
~N H N
~+
(CFiz~, (CHz~, 2 X -'--.- N H N
R
~ (~H~~J
wherein R and n are the same as defined herein above. X is an anion which serves to provide electronic neutrality to the bis-quaternary cis tetracycle. Those of ordinary skill in the art recognize that the term "electronic neutrality" refers to "a sufficient amount of an anionic species which satisfies the molecular charge balance requirements" and that a mixture of mono-, di-, tri-.
etc. electronic species may be use herein. X preferably has unit negative charge, for example, 1 S halogen, tosylate, methylsulfate, ethylsulfate. However, X may have more than one negative charge, for example, sulfate, in which case the formulator requires only half the amount necessary when using a unit negative-charged anion. Preferred X is chloride, bromide, iodide, sulfate, ethyl sulfate, methyl sulfate, tosylate, mesylate, triflate, and mixtures thereof.
STEP (a) Hydrogenation - Reductive Cleavage Step (a) comprises the reductive cleavage via catalytic hydrogenation as outlined in the following scheme:
(CH=~, ~ ~ (CH=~, R
~N H N
/~ N N
(CH=~, fCH=~, H~ (C~ R R ~ H:~
, / 2X- /
~N H N~ catalyst ~N/ y R
(CH~~,~
(CH=~,~
wherein the cis-tetracycle bis quaternary salt is converted to the cross-bridged tetraaza macrocycle.
3 Step (a) is conducted in the presence of a catalyst, preferably a supported catalyst. Non-limiting examples of catalysts include platinum on carbon, palladium on carbon (Pd/C), palladium hydroxide on carbon (Pd(OH),iC), rhodium on carbon (Rh/C), Raney nickel, and mixtures thereof. A preferred catalyst is Pd(OH)Z/C. The supported catalysts may comprise from about 1% to about 50% by weight of transition metal, however, the pure metal, i.e. palladium, can be used without the need for a "support", i.e., carbon. A "catalytic amount"
of catalyst is sufficient to provide the reduction of step (a). For the purposes of the present invention the term catalytic amount is defined as "from about 1 ppm of a S% by weight transition metal catalyst".
However, the formulator, due to poisoning of the catalyst surface by reaction products may use more than a catalytic amount of a catalyst. The amount of catalyst used in step (a) of the present invention is preferably from about 10 ppm of a catalyst which contains from about 5% to 50% by weight, of a transition metal, more preferably from about 100 ppm, yet more preferably from about 0.1% by weight, of a transition metal supported catalyst. A reaction solution which comprises 0.1% by weight, of a transition metal supported catalyst, said catalyst comprising, for example, 10% by weight.of palladium on carbon, has 0.01 % transition metal or 100 ppm transition metal present.
The amount of hydrogen gas present in step (a) of the present invention need only be enough to sufficiently saturate the catalyst surface, preferably the hydrogen pressure is from 200 psi, more preferably from 400 psi, most preferably from 800 psi to about 2000 psi, more preferably to 1000 psi.
Step (a) of the present process can be conducted at a temperature of from 20° C, preferably from about 40° C, more preferably from about 60° C to about 100° C, preferably to about 90° C, more preferably to about 80° C, most preferably to about 65° C.
The pH under which Step (a) must be conducted is at least 8, preferably at least 10, more preferably at least about 11. Preferably the base which is used to adjust the pH is in the form of an aqueous solution. Preferred bases are selected from the group consisting of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, and mixtures thereof. As a non-limiting example, it is satisfactory to use a sufficient amount of 1 M
(molar) aqueous base to adjust the pH to the required level. A convenient and preferred base is potassium carbonate.
As a suitable alternative, Step (a) can be conducted in the presence of a solvent other than water, or in the absence of water. A mixture of a suitable solvent and water is a suitable means for conducting the hydrogenation process of the present invention. In the case where water is absent, sufficient base must be present to stabilize the transition state of the reactants and products during hydrogenation. Non-limiting examples of solvents include methanol, ethanol, n-propanol, isopropanol, N,N-dimethyl formamide, n-butanol, iso-butanol, tert-butanol, and mixtures thereof; preferred solvents are selected from the group consisting of ethanol, n-propanol, N,N-dimethyl formamide, and mixtures thereof. VVhen a solvent is present and the base is in the form of an aqueous solution, the ratio of said volume of an aqueous base, to said solvent is from about 1:10 to about 1:1, preferably the ratio of the volume of aqueous base to solvent is 1:4. It is desirable, but not a requirement, that the aqueous base and solvent form a two phase system.
The process of the present invention comprises an optional, although preferred, Step (b) which is an isolation step. Typically this step involves filtration of the reaction solution to remove the catalyst. In addition, this step may comprise a neutralization step, however, the product can be isolated or removed from the reaction matrix in any manner which the formulator desires.
When filtration of the catalyst is a desired step, the reaction solution containing the cross-bridged ligand is filtered to remove the catalyst to form a crude filtrate.
This crude filtrate can be neutralized or the tetraaza macrocyclic ligand can be isolated by extraction or crystallization directly from the preferably aqueous solution.
Steps {a) and (b) and any optional extensions thereto, for example, a crystallization step, a solvent drying step, a purging step, may be suitably adapted for either batch processes or continuous processes, for example, continuous flow processes. As mentioned herein, the process of the present invention may comprise other optional steps as deemed necessary and/or desirable by the formulator. These optional steps may include but are not limited to, pre-saturation of the catalyst with hydrogen, drawing a vacuum on the system, and recovery of the catalyst and solvents.
Preferably the ligands formed by the process of the present invention are converted into manganese containing transition metal catalysts in a subsequent, however optional, process step.
The bleach catalysts comprise a central manganese atom and a cross-branched ligand formed by the process of the present invention. The final bleach catalyst may comprise one or more other compatible ligands inter alia chlorine atom. The preferred catalysts are suitable as bleaching agents.
The following is a non-limiting example of the process of the present invention.
Preparation of 5,12-diethyl-1,5,8,12-tetraaza-bicvclo(6.6.21hexadecane To a thick walled, glass autoclave sleeve is added the bis-quaternary cis tetracycle having the formula:
~ HzCH3 N H N
TETRAAZA MACROCYCLES
FIELD OF THE INVENTION
The present invention relates to an improved process for preparing cross-bridged tetraaza macrocycles, said macrocycles suitable as ligands for use in preparing transition metal complexes. The present invention provides a process which is well suited for use in industrial and other commercial preparations of the herein described crossed-bridged macrocycles.
BACKGROUND OF THE INVENTION
Tetraaza macrocyclics, for example, cyclam, have been prepared in numerous ways, however, there is a paucity of information relating to the preparation of cross-bridged tetraaza macrocyclics inter alia bis N-substituted tetraaza macrocyclics inter alia 5,12 dialkyl 1,5,8,12-tetraaza-bicyclo[6.6.2]hexadecanes which have recently found wide applicability as ligands especially in the area of transition metal catalysts inter alia bleach catalysts.
WO 98/39335 A1 "Improved Methods of Making Cross-Bridged Macropoly-cycles"
discloses a rational procedure for preparing cross bridged macropolycyclic ligands which is amenable to high yields necessary for industrial scale-up. However, the reductive ring cleavage step which results in bicyclo bridged-ring formation utilizes a borohydride reducing agent. This type of reducing agent can place constraints on the formulator. For example, the need to break up the amine/borohydride complex during work-up and the proper recovery and disposal of boron waste products adds cost to the process. Also, if excess borohydride is needed, this requires neutralization which involves the use of acid and the evolution of large quantities of hydrogen gas.
Therefore, a need exists for a highly quantitative, preferably catalytic, process for preparing cross-bridged macropolycyclic ligands which is adaptable to either continuous flow processes or batch preparations.
SUMMARY OF THE INVENTION
The present invention meets the aforementioned needs in that it has been surprisingly discovered that select bis N-substituted tetraaza macrocyclics can be converted to cross-bridged macropolycyclic ligands via catalytic hydrogenation.
A first aspect of the present invention relates to a process for preparing a tetraaza macrocyclic ligand having the formula:
(CHz~,~
~-N
(CH~~, R R {CHz~, ~N N
~ (~Hz~J
wherein each R is independently C,-C8 linear or branched alkyl, -(CH,)rCO~M, and mixtures thereof, preferably both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3; said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
(CHz~, R
~N H N
(CHz~, (CHz~, \ / 2X-~N H N
R J
/ ~ (CHz~,~
wherein X is an anion which provides charge neutrality, with from about 1 ppm of a transition metal hydrogenation catalyst at a pH of at least $ to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified.
All temperatures are in degrees Celsius (o C) unless otherwise specified. All documents cited are in relevant pan, incorporated herein by reference.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the catalytic hydrogenation of tetraaza macrocycles having the formula:
~(cH,~,~ /R
NI H IN
(CH~~, (CH=~, _ ~ / 2X
'-N H N
R
/ ~(CH.~,J
wherein the covalent bond between the N-substituted quaternary ring nitrogen and the bridging carbon is broken and a cross-bridged macrocyclic ligand having the formula:
(CH:~, ~--N i -~
(cH~~, R R (CH:~, ~N/ N
~ (~H~~J
is the resulting product.
In the above formula each R is independently C,-Ca linear or branched alkyl, -(CH,)rCO~M, and mixtures thereof, preferably both of the R units are not methyl; more preferably one R unit is methyl and the other R unit is selected from the group consisting of ethyl, propyl, butyl, pentyl, hexyl, and mixtures thereof of the methyl/alkyl R unit mixtures preferably one R is methyl and the other R is ethyl or propyl. A most preferred ligand consists of a unit wherein one R unit is methyl and the other R unit is ethyl. A preferred ligand is a macrocyclic ring wherein each R unit is ethyl. M is hydrogen or a salt forming cation, non-limiting examples of which are sodium, potassium, calcium, ammonium. When R is -(CH~)xCO~M the index x has the value from 1 to about 6, preferably x is 1. The index n defines the size of the macrocyclic ring. The index n has the value of from 0 to about 3. A preferred macrocyclic ring has one opposite set of n indices equal to 1 and the other set of n indices equal to 0 as in the general formula:
N N
R R
N N
wherein R is the same as defined herein above.
Preferred ligands according to the present invention comprise R unit pairs which are selected from the group consisting of methyl and ethyl, diethyl, methyl and propyl, ethyl and propyl, methyl and butyl. ethyl and butyl, and mixtures thereof.
The starting materials for the process of the present invention are tetraaza macrocyclic ligand precursors, or alternatively, bis-quaternary cis tetracycles, having the formula:
(CH:~, R
~N H N
~+
(CFiz~, (CHz~, 2 X -'--.- N H N
R
~ (~H~~J
wherein R and n are the same as defined herein above. X is an anion which serves to provide electronic neutrality to the bis-quaternary cis tetracycle. Those of ordinary skill in the art recognize that the term "electronic neutrality" refers to "a sufficient amount of an anionic species which satisfies the molecular charge balance requirements" and that a mixture of mono-, di-, tri-.
etc. electronic species may be use herein. X preferably has unit negative charge, for example, 1 S halogen, tosylate, methylsulfate, ethylsulfate. However, X may have more than one negative charge, for example, sulfate, in which case the formulator requires only half the amount necessary when using a unit negative-charged anion. Preferred X is chloride, bromide, iodide, sulfate, ethyl sulfate, methyl sulfate, tosylate, mesylate, triflate, and mixtures thereof.
STEP (a) Hydrogenation - Reductive Cleavage Step (a) comprises the reductive cleavage via catalytic hydrogenation as outlined in the following scheme:
(CH=~, ~ ~ (CH=~, R
~N H N
/~ N N
(CH=~, fCH=~, H~ (C~ R R ~ H:~
, / 2X- /
~N H N~ catalyst ~N/ y R
(CH~~,~
(CH=~,~
wherein the cis-tetracycle bis quaternary salt is converted to the cross-bridged tetraaza macrocycle.
3 Step (a) is conducted in the presence of a catalyst, preferably a supported catalyst. Non-limiting examples of catalysts include platinum on carbon, palladium on carbon (Pd/C), palladium hydroxide on carbon (Pd(OH),iC), rhodium on carbon (Rh/C), Raney nickel, and mixtures thereof. A preferred catalyst is Pd(OH)Z/C. The supported catalysts may comprise from about 1% to about 50% by weight of transition metal, however, the pure metal, i.e. palladium, can be used without the need for a "support", i.e., carbon. A "catalytic amount"
of catalyst is sufficient to provide the reduction of step (a). For the purposes of the present invention the term catalytic amount is defined as "from about 1 ppm of a S% by weight transition metal catalyst".
However, the formulator, due to poisoning of the catalyst surface by reaction products may use more than a catalytic amount of a catalyst. The amount of catalyst used in step (a) of the present invention is preferably from about 10 ppm of a catalyst which contains from about 5% to 50% by weight, of a transition metal, more preferably from about 100 ppm, yet more preferably from about 0.1% by weight, of a transition metal supported catalyst. A reaction solution which comprises 0.1% by weight, of a transition metal supported catalyst, said catalyst comprising, for example, 10% by weight.of palladium on carbon, has 0.01 % transition metal or 100 ppm transition metal present.
The amount of hydrogen gas present in step (a) of the present invention need only be enough to sufficiently saturate the catalyst surface, preferably the hydrogen pressure is from 200 psi, more preferably from 400 psi, most preferably from 800 psi to about 2000 psi, more preferably to 1000 psi.
Step (a) of the present process can be conducted at a temperature of from 20° C, preferably from about 40° C, more preferably from about 60° C to about 100° C, preferably to about 90° C, more preferably to about 80° C, most preferably to about 65° C.
The pH under which Step (a) must be conducted is at least 8, preferably at least 10, more preferably at least about 11. Preferably the base which is used to adjust the pH is in the form of an aqueous solution. Preferred bases are selected from the group consisting of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, and mixtures thereof. As a non-limiting example, it is satisfactory to use a sufficient amount of 1 M
(molar) aqueous base to adjust the pH to the required level. A convenient and preferred base is potassium carbonate.
As a suitable alternative, Step (a) can be conducted in the presence of a solvent other than water, or in the absence of water. A mixture of a suitable solvent and water is a suitable means for conducting the hydrogenation process of the present invention. In the case where water is absent, sufficient base must be present to stabilize the transition state of the reactants and products during hydrogenation. Non-limiting examples of solvents include methanol, ethanol, n-propanol, isopropanol, N,N-dimethyl formamide, n-butanol, iso-butanol, tert-butanol, and mixtures thereof; preferred solvents are selected from the group consisting of ethanol, n-propanol, N,N-dimethyl formamide, and mixtures thereof. VVhen a solvent is present and the base is in the form of an aqueous solution, the ratio of said volume of an aqueous base, to said solvent is from about 1:10 to about 1:1, preferably the ratio of the volume of aqueous base to solvent is 1:4. It is desirable, but not a requirement, that the aqueous base and solvent form a two phase system.
The process of the present invention comprises an optional, although preferred, Step (b) which is an isolation step. Typically this step involves filtration of the reaction solution to remove the catalyst. In addition, this step may comprise a neutralization step, however, the product can be isolated or removed from the reaction matrix in any manner which the formulator desires.
When filtration of the catalyst is a desired step, the reaction solution containing the cross-bridged ligand is filtered to remove the catalyst to form a crude filtrate.
This crude filtrate can be neutralized or the tetraaza macrocyclic ligand can be isolated by extraction or crystallization directly from the preferably aqueous solution.
Steps {a) and (b) and any optional extensions thereto, for example, a crystallization step, a solvent drying step, a purging step, may be suitably adapted for either batch processes or continuous processes, for example, continuous flow processes. As mentioned herein, the process of the present invention may comprise other optional steps as deemed necessary and/or desirable by the formulator. These optional steps may include but are not limited to, pre-saturation of the catalyst with hydrogen, drawing a vacuum on the system, and recovery of the catalyst and solvents.
Preferably the ligands formed by the process of the present invention are converted into manganese containing transition metal catalysts in a subsequent, however optional, process step.
The bleach catalysts comprise a central manganese atom and a cross-branched ligand formed by the process of the present invention. The final bleach catalyst may comprise one or more other compatible ligands inter alia chlorine atom. The preferred catalysts are suitable as bleaching agents.
The following is a non-limiting example of the process of the present invention.
Preparation of 5,12-diethyl-1,5,8,12-tetraaza-bicvclo(6.6.21hexadecane To a thick walled, glass autoclave sleeve is added the bis-quaternary cis tetracycle having the formula:
~ HzCH3 N H N
2 Br -N H N
(3.0 g, 6.8 mmol) and a 1M aqueous solution of KZC03 (30 mL). The solution is agitated to dissolve the substrate then 20°.o Pd(OH)~/carbon (0.7 g, 1.0 mmol) is added. The glass sleeve is placed into a rocking autoclave and hydrogenated at 65° C with 1900 psig hydrogen for 4 hours.
The reaction is cooled and the solution filtered through glass fiber filter paper to remove the catalyst and the filtrate is reduced to a white solid under vacuum. The white solid is suspended in refluxing ethanol and the un-dissolved inorganic salts are collected by filtration. After concentrating the filtrate under vacuum, the resulting oily residue is dissolved in aqueous 4M
KOH (4 mL) and extracted three times with 25 mL portions of toluene. The toluene extracts are combined and concentrated in vacuo to afford 5,12-diethyl-1,5,8,12-tetraaza-bicyclo[6.6.2Jhexadecane (1.56 g) in 81% yield as a clear oil.
The following is an example of an optional, but preferred step of the process of the present invention which is conversion to a manganese transition metal bleach catalyst.
Preparation of dichloro 5,12-diethyl-1,5,8,12-tetraaza-bicvclof6.6.Zlhexadecane maneanese To a 100 mL reaction flask is charged anhydrous acetonitrile (50 mL) and 5,12-diethyl-1,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane (1.4 g, 5 mmol). The resulting suspension is degassed under vacuum with subsequent re-filling with argon. This process is repeated six times.
Manganese(II) chloride (0.590 g, 4.7 mmol) is added and the reaction is refluxed for 3 hours.
The resulting solution is filtered through glass-fiber filter paper. The resulting filtrate is concentrated under reduced pressure at 45° C to afford a solid. The solid is suspended in toluene (~0 mL) and the resulting dark supernatant is discarded. Treatment with toluene is repeated five times. The resulting solid is dried under vacuum to yield dichloro 5,12-diethyl-1,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane manganese (1.48 g, 73% yield).
(3.0 g, 6.8 mmol) and a 1M aqueous solution of KZC03 (30 mL). The solution is agitated to dissolve the substrate then 20°.o Pd(OH)~/carbon (0.7 g, 1.0 mmol) is added. The glass sleeve is placed into a rocking autoclave and hydrogenated at 65° C with 1900 psig hydrogen for 4 hours.
The reaction is cooled and the solution filtered through glass fiber filter paper to remove the catalyst and the filtrate is reduced to a white solid under vacuum. The white solid is suspended in refluxing ethanol and the un-dissolved inorganic salts are collected by filtration. After concentrating the filtrate under vacuum, the resulting oily residue is dissolved in aqueous 4M
KOH (4 mL) and extracted three times with 25 mL portions of toluene. The toluene extracts are combined and concentrated in vacuo to afford 5,12-diethyl-1,5,8,12-tetraaza-bicyclo[6.6.2Jhexadecane (1.56 g) in 81% yield as a clear oil.
The following is an example of an optional, but preferred step of the process of the present invention which is conversion to a manganese transition metal bleach catalyst.
Preparation of dichloro 5,12-diethyl-1,5,8,12-tetraaza-bicvclof6.6.Zlhexadecane maneanese To a 100 mL reaction flask is charged anhydrous acetonitrile (50 mL) and 5,12-diethyl-1,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane (1.4 g, 5 mmol). The resulting suspension is degassed under vacuum with subsequent re-filling with argon. This process is repeated six times.
Manganese(II) chloride (0.590 g, 4.7 mmol) is added and the reaction is refluxed for 3 hours.
The resulting solution is filtered through glass-fiber filter paper. The resulting filtrate is concentrated under reduced pressure at 45° C to afford a solid. The solid is suspended in toluene (~0 mL) and the resulting dark supernatant is discarded. Treatment with toluene is repeated five times. The resulting solid is dried under vacuum to yield dichloro 5,12-diethyl-1,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane manganese (1.48 g, 73% yield).
Claims (12)
1. A process for preparing a tetraaza macrocyclic ligand having the formula:
wherein each R is independently C1-C8 linear or branched alkyl, -(CH2)x CO2M, and mixtures thereof, provided both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3;
said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X- is an anion which provides charge neutrality, with from 1 ppm of a transition metal hydrogenation catalyst at a pH of at least 8 to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
wherein each R is independently C1-C8 linear or branched alkyl, -(CH2)x CO2M, and mixtures thereof, provided both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3;
said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X- is an anion which provides charge neutrality, with from 1 ppm of a transition metal hydrogenation catalyst at a pH of at least 8 to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
2. A process according to Claim 1 wherein said transition metal hydrogenation catalyst is selected from the group consisting of platinum, palladium, palladium hydroxide, rhodium, Raney nickel, and mixtures thereof.
3. A process according to either of Claims 1 or 2 wherein step (a) is conducted at a temperature of from 40° C to 100° C, at a pH of at least 10, and in the presence of a solvent, said solvent selected from the group consisting of water, N,N-dimethyl formamide, methanol, ethanol, isopropanol, n-butanol, iso-butanol, tert-butanol, and mixtures thereof.
4. A process according any of Claims 1-3 wherein said precursor has the formula:
wherein R and X are the same as defined herein above.
wherein R and X are the same as defined herein above.
5. A process according to any of Claims 1-4 wherein each R is ethyl.
6. A process according to any of Claims 1-5 wherein one R is methyl and one R
is ethyl.
is ethyl.
7. A process for preparing a tetraaza macrocyclic ligand having the formula:
wherein one R unit is methyl and the other R unit is selected from the group consisting of ethyl, propyl, butyl, pentyl, hexyl, and mixtures thereof; said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X - is an anion which provides charge neutrality, with from 1 ppm of a palladium hydrogenation catalyst at a pH of at least 10 to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
wherein one R unit is methyl and the other R unit is selected from the group consisting of ethyl, propyl, butyl, pentyl, hexyl, and mixtures thereof; said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X - is an anion which provides charge neutrality, with from 1 ppm of a palladium hydrogenation catalyst at a pH of at least 10 to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
8. A process for preparing a tetraaza macrocyclic ligand having the formula;
wherein each R is independently C1-C8 linear or branched alkyl, -(CH2)x CO2M, and mixtures thereof, provided both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3;
said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X - is an anion which provides charge neutrality, with from 1 ppm of a palladium hydrogenation catalyst, said palladium catalyst selected from the group consisting of supported palladium(0), palladium hydroxide, and mixtures thereof; at a pH of at least 8; in the presence of a solvent, said solvent selected from the group consisting of water, methanol, ethanol, N,N-dimethyl formamide, n-butanol, iso-butanol, tert-butanol, and mixture thereof; at a temperature of from 0° C to 100° C; to form a tetraaza macrocyclic ligand; and b) removing the catalyst by filtration to form a crude filtrate;
c) optionally isolating said ligand by crystallizing, extracting, distilling, or other suitable means.
wherein each R is independently C1-C8 linear or branched alkyl, -(CH2)x CO2M, and mixtures thereof, provided both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3;
said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X - is an anion which provides charge neutrality, with from 1 ppm of a palladium hydrogenation catalyst, said palladium catalyst selected from the group consisting of supported palladium(0), palladium hydroxide, and mixtures thereof; at a pH of at least 8; in the presence of a solvent, said solvent selected from the group consisting of water, methanol, ethanol, N,N-dimethyl formamide, n-butanol, iso-butanol, tert-butanol, and mixture thereof; at a temperature of from 0° C to 100° C; to form a tetraaza macrocyclic ligand; and b) removing the catalyst by filtration to form a crude filtrate;
c) optionally isolating said ligand by crystallizing, extracting, distilling, or other suitable means.
9. A process according to Claim 8 wherein said process further comprises the step of treating said ligand with manganese to form a cross-bridged tetraaza macrocyclic transition metal catalyst.
10. A process for preparing a tetraaza macrocyclic ligand having the formula:
wherein R units are R unit pairs selected from the group consisting of methyl and ethyl, diethyl, methyl and propyl, ethyl and propyl, methyl and butyl, ethyl and butyl, and mixtures thereof; M is hydrogen or a salt forming canon; x is from 1 to 6;
each index n is independently from 0 to 3; said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X - is an anion which provides charge neutrality, with from 1 ppm of a transition metal hydrogenation catalyst at a pH of at least 8 to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
wherein R units are R unit pairs selected from the group consisting of methyl and ethyl, diethyl, methyl and propyl, ethyl and propyl, methyl and butyl, ethyl and butyl, and mixtures thereof; M is hydrogen or a salt forming canon; x is from 1 to 6;
each index n is independently from 0 to 3; said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X - is an anion which provides charge neutrality, with from 1 ppm of a transition metal hydrogenation catalyst at a pH of at least 8 to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
11. A transition metal catalyst comprising:
a) a crossed-bridged ligand having the formula:
wherein each R is independently C1-C8 linear or branched alkyl, -(CH2)x CO2M, and mixtures thereof, provided both of the R units are not methyl or butyl; M
is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3;
b) manganese; and c) optionally one or more compatible ligands.
a) a crossed-bridged ligand having the formula:
wherein each R is independently C1-C8 linear or branched alkyl, -(CH2)x CO2M, and mixtures thereof, provided both of the R units are not methyl or butyl; M
is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3;
b) manganese; and c) optionally one or more compatible ligands.
12. A compound according to Claim 11 having the formula:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11030998P | 1998-11-30 | 1998-11-30 | |
US60/110,309 | 1998-11-30 | ||
PCT/US1999/027316 WO2000032601A2 (en) | 1998-11-30 | 1999-11-18 | Process for preparing cross-bridged tetraaza macrocycles |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2348893A1 true CA2348893A1 (en) | 2000-06-08 |
Family
ID=22332328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002348893A Abandoned CA2348893A1 (en) | 1998-11-30 | 1999-11-18 | Process for preparing cross-bridged tetraaza macrocycles |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1135392A2 (en) |
JP (1) | JP2002531457A (en) |
AU (1) | AU2026100A (en) |
CA (1) | CA2348893A1 (en) |
WO (1) | WO2000032601A2 (en) |
Families Citing this family (252)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004509924A (en) * | 2000-09-25 | 2004-04-02 | ザ、プロクター、エンド、ギャンブル、カンパニー | MRI image enhancing composition |
FR2830253B1 (en) | 2001-09-28 | 2005-02-04 | Air Liquide | NOVEL PROCESS FOR THE PREPARATION OF C-FUNCTIONALIZED NITROGEN MACROCYCLES AND NOVEL INTERMEDIATES OBTAINED |
US7169744B2 (en) | 2002-06-06 | 2007-01-30 | Procter & Gamble Company | Organic catalyst with enhanced solubility |
US7557076B2 (en) | 2002-06-06 | 2009-07-07 | The Procter & Gamble Company | Organic catalyst with enhanced enzyme compatibility |
FR2856063B1 (en) * | 2003-06-13 | 2005-10-07 | Air Liquide | PROCESS FOR THE PREPARATION OF CIS-8B-METHYLDECAHYDRO-2A, 4A, 6A, 8A-TETRAAZACYCLOPENTA [FG] ACENAPHTHYLENE, OR CIS-DECAHYDRO-2A, 4A, 6A, 8A-TETRAAZACYCLOPENTA [FG] ACENAPHTHYLENE, CYCLENE, AND CYCLENES FUNCTIONALISED |
US8535927B1 (en) | 2003-11-19 | 2013-09-17 | Danisco Us Inc. | Micrococcineae serine protease polypeptides and compositions thereof |
US7985569B2 (en) | 2003-11-19 | 2011-07-26 | Danisco Us Inc. | Cellulomonas 69B4 serine protease variants |
EP2664670B1 (en) | 2003-12-03 | 2015-05-06 | Danisco US Inc. | Perhydrolase |
US20050181969A1 (en) | 2004-02-13 | 2005-08-18 | Mort Paul R.Iii | Active containing delivery particle |
US7425527B2 (en) | 2004-06-04 | 2008-09-16 | The Procter & Gamble Company | Organic activator |
US7686892B2 (en) | 2004-11-19 | 2010-03-30 | The Procter & Gamble Company | Whiteness perception compositions |
AR051659A1 (en) | 2005-06-17 | 2007-01-31 | Procter & Gamble | A COMPOSITION THAT INCLUDES AN ORGANIC CATALYST WITH IMPROVED ENZYMATIC COMPATIBILITY |
ES2415872T3 (en) | 2005-08-19 | 2013-07-29 | The Procter & Gamble Company | Solid laundry detergent composition comprising an anionic detersive surfactant and calcium enhancement technology |
US20070044824A1 (en) | 2005-09-01 | 2007-03-01 | Scott William Capeci | Processing system and method of processing |
JP2009509750A (en) | 2005-09-27 | 2009-03-12 | ザ・プロクター・アンド・ギャンブル・カンパニー | Microcapsule and manufacturing method thereof |
US20080293610A1 (en) | 2005-10-12 | 2008-11-27 | Andrew Shaw | Use and production of storage-stable neutral metalloprotease |
BRPI0617738A2 (en) | 2005-10-24 | 2011-08-02 | Procter & Gamble | tissue treatment compositions and systems comprising organosilicone microemulsions, and methods for using them |
EP2248882A1 (en) | 2006-01-23 | 2010-11-10 | The Procter and Gamble Company | Enzyme and fabric hueing agent containing compositions |
US7790666B2 (en) | 2006-01-23 | 2010-09-07 | The Procter & Gamble Company | Detergent compositions |
MX2008011072A (en) | 2006-02-28 | 2008-09-05 | Procter & Gamble | Benefit agent containing delivery particle. |
US7629158B2 (en) | 2006-06-16 | 2009-12-08 | The Procter & Gamble Company | Cleaning and/or treatment compositions |
WO2008016637A1 (en) | 2006-08-01 | 2008-02-07 | Appleton Papers Inc. | Benefit agent containing delivery particle |
JP2010509447A (en) | 2006-11-22 | 2010-03-25 | ザ プロクター アンド ギャンブル カンパニー | Beneficial agent-containing delivery particles |
US20080177089A1 (en) | 2007-01-19 | 2008-07-24 | Eugene Steven Sadlowski | Novel whitening agents for cellulosic substrates |
MX2009008790A (en) | 2007-02-15 | 2009-08-24 | Procter & Gamble | Benefit agent delivery compositions. |
EP2155844B1 (en) | 2007-06-05 | 2012-11-21 | The Procter & Gamble Company | Perfume systems |
EP2160176B1 (en) | 2007-06-11 | 2017-07-26 | The Procter and Gamble Company | Benefit agent containing delivery particle |
US8021436B2 (en) | 2007-09-27 | 2011-09-20 | The Procter & Gamble Company | Cleaning and/or treatment compositions comprising a xyloglucan conjugate |
US20090094006A1 (en) | 2007-10-03 | 2009-04-09 | William David Laidig | Modeling systems for consumer goods |
CN101868538B (en) | 2007-11-01 | 2013-07-10 | 丹尼斯科美国公司 | Production of thermolysin and variants thereof and use in liquid detergents |
EP2071017A1 (en) | 2007-12-04 | 2009-06-17 | The Procter and Gamble Company | Detergent composition |
EP2242829B1 (en) | 2008-01-04 | 2013-03-13 | The Procter & Gamble Company | Laundry detergent composition comprising a glycosyl hydrolase and a benefit agent containing delivery particle |
CA2709609C (en) | 2008-01-04 | 2013-05-28 | The Procter & Gamble Company | Glycosyl hydrolase enzyme and fabric hueing agent containing compositions |
EP2083065A1 (en) | 2008-01-22 | 2009-07-29 | The Procter and Gamble Company | Colour-Care Composition |
WO2009102755A1 (en) | 2008-02-11 | 2009-08-20 | Danisco Us Inc., Genencor Division | Enzyme with microbial lysis activity from trichoderma reesei |
AU2009214868A1 (en) | 2008-02-14 | 2009-08-20 | Danisco Us Inc. | Small enzyme-containing granules |
US20090209447A1 (en) | 2008-02-15 | 2009-08-20 | Michelle Meek | Cleaning compositions |
US7923426B2 (en) | 2008-06-04 | 2011-04-12 | The Procter & Gamble Company | Detergent composition |
CA2726370A1 (en) | 2008-06-06 | 2009-12-10 | Danisco Us Inc. | Compositions and methods comprising variant microbial proteases |
EP2272941B1 (en) | 2008-06-20 | 2013-08-14 | The Procter & Gamble Company | Laundry composition |
EP2135933B1 (en) | 2008-06-20 | 2013-04-03 | The Procter and Gamble Company | Laundry composition |
BRPI0916612A2 (en) | 2008-07-30 | 2015-11-10 | Procter & Gamble Comapny | release particle |
EP2166077A1 (en) | 2008-09-12 | 2010-03-24 | The Procter and Gamble Company | Particles comprising a hueing dye |
EP2166078B1 (en) | 2008-09-12 | 2018-11-21 | The Procter & Gamble Company | Laundry particle made by extrusion comprising a hueing dye |
EP2163608A1 (en) | 2008-09-12 | 2010-03-17 | The Procter & Gamble Company | Laundry particle made by extrusion comprising a hueing dye and fatty acid soap |
WO2010053940A1 (en) | 2008-11-07 | 2010-05-14 | The Procter & Gamble Company | Benefit agent containing delivery particle |
WO2010056634A1 (en) | 2008-11-11 | 2010-05-20 | Danisco Us Inc. | Compositions and methods comprising a subtilisin variant |
BR122013014156A2 (en) | 2008-11-11 | 2015-07-14 | Danisco Us Inc | Cleaning composition comprising subtilisin variants as well as cleaning process |
CN102209777B (en) | 2008-11-11 | 2014-02-12 | 丹尼斯科美国公司 | Compositions and methods comprising subtilisin variant |
BR122013014157A2 (en) | 2008-11-11 | 2018-11-13 | Danisco Us Inc. | cleaning compositions comprising bacillus subtilisin variants as well as cleaning process |
MX2011005801A (en) | 2008-12-01 | 2011-06-20 | Procter & Gamble | Perfume systems. |
US8754028B2 (en) | 2008-12-16 | 2014-06-17 | The Procter & Gamble Company | Perfume systems |
CN102361965A (en) | 2009-04-02 | 2012-02-22 | 宝洁公司 | Composition comprising delivery particles |
WO2011002476A1 (en) | 2009-06-30 | 2011-01-06 | The Procter & Gamble Company | Fabric care compositions comprising cationic polymers and amphoteric |
US20100325812A1 (en) | 2009-06-30 | 2010-12-30 | Rajan Keshav Panandiker | Rinse Added Aminosilicone Containing Compositions and Methods of Using Same |
US20110005001A1 (en) | 2009-07-09 | 2011-01-13 | Eric San Jose Robles | Detergent Composition |
CN102471731A (en) | 2009-07-10 | 2012-05-23 | 宝洁公司 | Compositions containing benefit agent delivery particles |
WO2011005932A1 (en) | 2009-07-10 | 2011-01-13 | The Procter & Gamble Company | Compositions containing benefit agent delivery particles |
CN102471733A (en) | 2009-07-27 | 2012-05-23 | 宝洁公司 | Detergent composition |
EP3255135B1 (en) | 2009-11-06 | 2019-01-02 | The Procter & Gamble Company | High-efficiency perfume capsules |
CN102762222B (en) | 2009-12-09 | 2015-11-25 | 丹尼斯科美国公司 | Comprise compositions and the method for ease variants |
WO2011072117A1 (en) | 2009-12-09 | 2011-06-16 | The Procter & Gamble Company | Fabric and home care products |
MX323219B (en) | 2009-12-18 | 2014-08-28 | Procter & Gamble | Perfumes and perfume encapsulates. |
WO2011075556A1 (en) | 2009-12-18 | 2011-06-23 | The Procter & Gamble Company | Composition comprising encapsulates, and process for making them |
WO2011084599A1 (en) | 2009-12-21 | 2011-07-14 | Danisco Us Inc. | Detergent compositions containing bacillus subtilis lipase and methods of use thereof |
US20120258507A1 (en) | 2009-12-21 | 2012-10-11 | Danisco Us Inc. | Detergent compositions containing thermobifida fusca lipase and methods of use thereof |
US8741609B2 (en) | 2009-12-21 | 2014-06-03 | Danisco Us Inc. | Detergent compositions containing Geobacillus stearothermophilus lipase and methods of use thereof |
MX2012008498A (en) | 2010-01-21 | 2012-08-17 | Procter & Gamble | Process of preparing a particle. |
US20110201537A1 (en) | 2010-02-12 | 2011-08-18 | Jennifer Beth Ponder | Benefit compositions comprising crosslinked polyglycerol esters |
US20110201533A1 (en) | 2010-02-12 | 2011-08-18 | Jennifer Beth Ponder | Benefit compositions comprising polyglycerol esters |
US20110201534A1 (en) | 2010-02-12 | 2011-08-18 | Jennifer Beth Ponder | Benefit compositions comprising polyglycerol esters |
WO2011100420A1 (en) | 2010-02-12 | 2011-08-18 | The Procter & Gamble Company | Benefit compositions comprising crosslinked polyglycerol esters |
WO2011109322A1 (en) | 2010-03-04 | 2011-09-09 | The Procter & Gamble Company | Detergent composition |
JP6018044B2 (en) | 2010-04-15 | 2016-11-02 | ダニスコ・ユーエス・インク | Compositions and methods comprising protease variants |
MX2012012242A (en) | 2010-04-19 | 2012-11-23 | Procter & Gamble | Detergent composition. |
US9186642B2 (en) | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
US9993793B2 (en) | 2010-04-28 | 2018-06-12 | The Procter & Gamble Company | Delivery particles |
HUE045202T2 (en) | 2010-05-06 | 2019-12-30 | Procter & Gamble | Consumer products with protease variants |
BR112012029188B1 (en) | 2010-05-18 | 2020-12-08 | Milliken & Company | optical whitening compounds and compositions comprising the same |
CN102906239B (en) | 2010-05-18 | 2015-09-09 | 美利肯公司 | White dyes and containing its composition |
BR112012030525A2 (en) | 2010-05-26 | 2016-08-09 | Procter & Gamble | encapsulated |
WO2011150157A2 (en) | 2010-05-28 | 2011-12-01 | Danisco Us Inc. | Detergent compositions containing streptomyces griseus lipase and methods of use thereof |
US8476216B2 (en) | 2010-05-28 | 2013-07-02 | Milliken & Company | Colored speckles having delayed release properties |
EP2585568A1 (en) | 2010-06-22 | 2013-05-01 | The Procter and Gamble Company | Perfume systems |
CA2799582C (en) | 2010-06-22 | 2017-01-03 | The Procter & Gamble Company | Perfume systems |
EP2588587B1 (en) | 2010-06-30 | 2018-08-22 | The Procter and Gamble Company | Rinse added aminosilicone containing compositions and methods of using same |
CA2803685C (en) | 2010-07-20 | 2015-05-05 | The Procter & Gamble Company | Delivery particles with a plurality of cores |
MX2013000792A (en) | 2010-07-20 | 2013-02-27 | Procter & Gamble | Particles with a plurality of coatings. |
CA2810534C (en) | 2010-09-20 | 2017-04-18 | The Procter & Gamble Company | Non-fluoropolymer surface protection composition |
JP2013538282A (en) | 2010-09-20 | 2013-10-10 | ザ プロクター アンド ギャンブル カンパニー | Non-fluoropolymer surface protection composition |
BR112013004895B1 (en) | 2010-09-20 | 2021-07-06 | Wacker Chemie Ag | fabric care composition and method of providing stain repellency to a textile product |
WO2012057781A1 (en) | 2010-10-29 | 2012-05-03 | The Procter & Gamble Company | Cleaning and/or treatment compositions comprising a fungal serine protease |
WO2011026154A2 (en) | 2010-10-29 | 2011-03-03 | The Procter & Gamble Company | Cleaning and/or treatment compositions |
US8715368B2 (en) | 2010-11-12 | 2014-05-06 | The Procter & Gamble Company | Thiophene azo dyes and laundry care compositions containing the same |
ES2436268T3 (en) | 2010-12-21 | 2013-12-30 | Procter & Gamble International Operations Sa | Encapsulated |
WO2012116021A1 (en) | 2011-02-25 | 2012-08-30 | Milliken & Company | Capsules and compositions comprising the same |
JP6283607B2 (en) | 2011-04-07 | 2018-02-21 | ザ プロクター アンド ギャンブル カンパニー | Personal cleansing composition with increased deposition of polyacrylate microcapsules |
US8980292B2 (en) | 2011-04-07 | 2015-03-17 | The Procter & Gamble Company | Conditioner compositions with increased deposition of polyacrylate microcapsules |
MX2013010983A (en) | 2011-04-07 | 2013-10-30 | Procter & Gamble | Shampoo compositions with increased deposition of polyacrylate microcapsules. |
EP2697352A1 (en) | 2011-04-12 | 2014-02-19 | The Procter and Gamble Company | Metal bleach catalysts |
US20140135252A1 (en) | 2011-04-29 | 2014-05-15 | Danisco Us Inc. | Detergent compositions containing geobacillus tepidamans mannanase and methods of use thereof |
US8802388B2 (en) | 2011-04-29 | 2014-08-12 | Danisco Us Inc. | Detergent compositions containing Bacillus agaradhaerens mannanase and methods of use thereof |
BR112013026675A2 (en) | 2011-04-29 | 2016-11-29 | Danisco Us Inc | detergent compositions containing bacillus sp. mannanase, and methods of use thereof |
BR112013027963A2 (en) | 2011-05-05 | 2016-11-29 | Danisco Us Inc | "Subtilisin variant with proteolytic activity, nucleic acid, expression vector, host cell, composition and cleaning method". |
MX357386B (en) | 2011-05-05 | 2018-07-06 | Procter & Gamble | Compositions and methods comprising serine protease variants. |
US20140371435A9 (en) | 2011-06-03 | 2014-12-18 | Eduardo Torres | Laundry Care Compositions Containing Thiophene Azo Dyes |
EP2537918A1 (en) | 2011-06-20 | 2012-12-26 | The Procter & Gamble Company | Consumer products with lipase comprising coated particles |
AR086558A1 (en) | 2011-06-23 | 2014-01-08 | Procter & Gamble | PERFUME SYSTEM |
JP5948417B2 (en) | 2011-08-10 | 2016-07-06 | ザ プロクター アンド ギャンブル カンパニー | Inclusion body |
BR112014004444A2 (en) | 2011-08-31 | 2017-03-21 | Danisco Us Inc | compositions and methods comprising a lipolytic enzyme variant |
CN103874758A (en) | 2011-09-13 | 2014-06-18 | 宝洁公司 | Encapsulates |
EP2581438A1 (en) | 2011-10-12 | 2013-04-17 | The Procter and Gamble Company | Detergent composition |
BR112014014410A2 (en) | 2011-12-22 | 2019-09-24 | Danisco Us Inc | compositions and methods comprising a lipolytic enzyme variant |
EP3109309B1 (en) | 2012-01-18 | 2022-06-08 | The Procter & Gamble Company | Perfume systems |
MX353911B (en) | 2012-02-03 | 2018-02-02 | Novozymes As | Lipase variants and polynucleotides encoding same. |
MX353896B (en) | 2012-02-03 | 2018-02-01 | Procter & Gamble | Compositions and methods for surface treatment with lipases. |
IN2014DN07763A (en) | 2012-03-19 | 2015-05-15 | Milliken & Co | |
WO2013148639A1 (en) | 2012-03-26 | 2013-10-03 | The Procter & Gamble Company | Cleaning compositions comprising ph-switchable amine surfactants |
CN104204198B (en) | 2012-04-02 | 2018-09-25 | 诺维信公司 | Lipase Variant and the polynucleotides for encoding it |
CN104302753A (en) | 2012-05-16 | 2015-01-21 | 诺维信公司 | Compositions comprising lipase and methods of use thereof |
EP2674475A1 (en) | 2012-06-11 | 2013-12-18 | The Procter & Gamble Company | Detergent composition |
US9796952B2 (en) | 2012-09-25 | 2017-10-24 | The Procter & Gamble Company | Laundry care compositions with thiazolium dye |
EP2712915A1 (en) | 2012-10-01 | 2014-04-02 | The Procter and Gamble Company | Methods of treating a surface and compositions for use therein |
CN105026541A (en) | 2012-10-04 | 2015-11-04 | 艺康美国股份有限公司 | Pre-soak technology for laundry and other hard surface cleaning |
CN110093330B (en) | 2012-10-12 | 2023-11-28 | 丹尼斯科美国公司 | Compositions and methods comprising lipolytic enzyme variants |
US9095787B2 (en) | 2012-10-24 | 2015-08-04 | The Procter & Gamble Company | Compositions comprising anti-foams |
US9133421B2 (en) | 2012-10-24 | 2015-09-15 | The Procter & Gamble Company | Compositions comprising anti-foams |
CN104781400A (en) | 2012-11-05 | 2015-07-15 | 丹尼斯科美国公司 | Compositions and methods comprising thermolysin protease variants |
WO2014100018A1 (en) | 2012-12-19 | 2014-06-26 | Danisco Us Inc. | Novel mannanase, compositions and methods of use thereof |
ES2652301T3 (en) | 2013-03-05 | 2018-02-01 | The Procter & Gamble Company | Mixed sugar-based amide surfactant compositions |
CN105051174B (en) | 2013-03-21 | 2018-04-03 | 诺维信公司 | Polypeptide and their polynucleotides of coding with lipase active |
US10351833B2 (en) | 2013-05-14 | 2019-07-16 | Novozymes A/S | Detergent compositions |
US20140338134A1 (en) | 2013-05-20 | 2014-11-20 | The Procter & Gamble Company | Encapsulates |
EP2806018A1 (en) | 2013-05-20 | 2014-11-26 | The Procter & Gamble Company | Encapsulates |
JP6077177B2 (en) | 2013-05-28 | 2017-02-08 | ザ プロクター アンド ギャンブル カンパニー | Surface treatment composition containing photochromic dye |
EP3004314B1 (en) | 2013-05-29 | 2018-06-20 | Danisco US Inc. | Novel metalloproteases |
US20160108387A1 (en) | 2013-05-29 | 2016-04-21 | Danisco Us Inc. | Novel metalloproteases |
EP3882346A1 (en) | 2013-05-29 | 2021-09-22 | Danisco US Inc. | Novel metalloproteases |
EP3110833B1 (en) | 2013-05-29 | 2020-01-08 | Danisco US Inc. | Novel metalloproteases |
WO2015004102A1 (en) | 2013-07-09 | 2015-01-15 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
EP3696264B1 (en) | 2013-07-19 | 2023-06-28 | Danisco US Inc. | Compositions and methods comprising a lipolytic enzyme variant |
EP3044313B1 (en) | 2013-09-12 | 2019-11-06 | Danisco US Inc. | Compositions and methods comprising lg12-clade protease variants |
US9834682B2 (en) | 2013-09-18 | 2017-12-05 | Milliken & Company | Laundry care composition comprising carboxylate dye |
CA2921433A1 (en) | 2013-09-18 | 2015-03-26 | The Procter & Gamble Company | Laundry care composition comprising carboxylate dye |
WO2015042209A1 (en) | 2013-09-18 | 2015-03-26 | The Procter & Gamble Company | Laundry care compositions containing thiophene azo carboxylate dyes |
CA2921432A1 (en) | 2013-09-18 | 2015-03-26 | The Procter & Gamble Company | Laundry care composition comprising carboxylate dye |
ES2723948T3 (en) | 2013-12-13 | 2019-09-04 | Danisco Us Inc | Serine proteases from Bacillus species |
EP3910057A1 (en) | 2013-12-13 | 2021-11-17 | Danisco US Inc. | Serine proteases of the bacillus gibsonii-clade |
EP3097173B1 (en) | 2014-01-22 | 2020-12-23 | The Procter and Gamble Company | Fabric treatment composition |
WO2015112341A1 (en) | 2014-01-22 | 2015-07-30 | The Procter & Gamble Company | Fabric treatment composition |
WO2015112340A1 (en) | 2014-01-22 | 2015-07-30 | The Procter & Gamble Company | Method of treating textile fabrics |
WO2015112338A1 (en) | 2014-01-22 | 2015-07-30 | The Procter & Gamble Company | Method of treating textile fabrics |
CN106103721B (en) | 2014-03-12 | 2020-01-03 | 诺维信公司 | Polypeptides having lipase activity and polynucleotides encoding same |
CN106170546A (en) | 2014-03-21 | 2016-11-30 | 丹尼斯科美国公司 | The serine protease of bacillus |
EP3131921B1 (en) | 2014-04-15 | 2020-06-10 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
WO2015171592A1 (en) | 2014-05-06 | 2015-11-12 | Milliken & Company | Laundry care compositions |
WO2015181118A1 (en) | 2014-05-27 | 2015-12-03 | Novozymes A/S | Methods for producing lipases |
US10023852B2 (en) | 2014-05-27 | 2018-07-17 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
WO2016049397A1 (en) | 2014-09-26 | 2016-03-31 | The Procter & Gamble Company | Freshening compositions and devices comprising same |
DK3207129T3 (en) | 2014-10-17 | 2020-02-24 | Danisco Us Inc | SERIN PROTEAS OF THE BACILLUS ART |
WO2016069569A2 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
EP3212662B1 (en) | 2014-10-27 | 2020-04-08 | Danisco US Inc. | Serine proteases |
WO2016069544A1 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
US20170335306A1 (en) | 2014-10-27 | 2017-11-23 | Danisco Us Inc. | Serine proteases |
US20180010074A1 (en) | 2014-10-27 | 2018-01-11 | Danisco Us Inc. | Serine proteases of bacillus species |
AR102683A1 (en) | 2014-11-17 | 2017-03-15 | Procter & Gamble | BENEFIT AGENT SUPPLY COMPOSITIONS |
US10457921B2 (en) | 2014-12-05 | 2019-10-29 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
US20160230124A1 (en) | 2015-02-10 | 2016-08-11 | The Procter & Gamble Company | Liquid laundry cleaning composition |
US20180216090A1 (en) | 2015-03-12 | 2018-08-02 | Danisco Us Inc. | Compositions and methods comprising lg12-clade protease variants |
JP6545822B2 (en) | 2015-04-29 | 2019-07-17 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | Cloth processing method |
CN107548415A (en) | 2015-04-29 | 2018-01-05 | 宝洁公司 | The method of laundering of textile fabrics |
HUE043043T2 (en) | 2015-04-29 | 2019-07-29 | Procter & Gamble | Method of treating a fabric |
CN112143591A (en) | 2015-04-29 | 2020-12-29 | 宝洁公司 | Method for treating fabric |
EP3088506B1 (en) | 2015-04-29 | 2018-05-23 | The Procter and Gamble Company | Detergent composition |
CN111718806B (en) | 2015-05-04 | 2022-01-04 | 美利肯公司 | Leuco triphenylmethane colorants as bluing agents in laundry care compositions |
RU2733987C2 (en) | 2015-05-13 | 2020-10-09 | ДАНИСКО ЮЭс ИНК. | Versions of protease of aprl and application thereof |
EP3298121B1 (en) | 2015-05-19 | 2019-03-20 | Novozymes A/S | Odor reduction |
EP3310908B1 (en) | 2015-06-16 | 2020-08-05 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
US11499146B2 (en) | 2015-06-17 | 2022-11-15 | Danisco Us Inc. | Bacillus gibsonii-clade serine proteases |
WO2016205008A1 (en) | 2015-06-19 | 2016-12-22 | The Procter & Gamble Company | Computer-implemeted method of making perfumed goods |
EP3317407B1 (en) | 2015-07-01 | 2021-05-19 | Novozymes A/S | Methods of reducing odor |
CN114292829A (en) | 2015-07-06 | 2022-04-08 | 诺维信公司 | Lipase variants and polynucleotides encoding same |
US9902923B2 (en) | 2015-10-13 | 2018-02-27 | The Procter & Gamble Company | Polyglycerol dye whitening agents for cellulosic substrates |
US9976035B2 (en) | 2015-10-13 | 2018-05-22 | Milliken & Company | Whitening agents for cellulosic substrates |
US9777250B2 (en) | 2015-10-13 | 2017-10-03 | Milliken & Company | Whitening agents for cellulosic substrates |
US10597614B2 (en) | 2015-10-13 | 2020-03-24 | The Procter & Gamble Company | Whitening agents for cellulosic substrates |
US10155868B2 (en) | 2015-10-13 | 2018-12-18 | Milliken & Company | Whitening agents for cellulosic substrates |
US9745544B2 (en) | 2015-10-13 | 2017-08-29 | The Procter & Gamble Company | Whitening agents for cellulosic substrates |
CN108603183B (en) | 2015-11-05 | 2023-11-03 | 丹尼斯科美国公司 | Paenibacillus species and bacillus species mannanases |
EP3371308B1 (en) | 2015-11-05 | 2022-05-11 | Danisco US Inc. | Paenibacillus sp. mannanases |
JP2019502779A (en) | 2015-11-26 | 2019-01-31 | ザ プロクター アンド ギャンブル カンパニー | Liquid detergent composition containing protease and encapsulated lipase |
US10870838B2 (en) | 2015-12-01 | 2020-12-22 | Novozymes A/S | Methods for producing lipases |
US10308900B2 (en) | 2015-12-22 | 2019-06-04 | Milliken & Company | Occult particles for use in granular laundry care compositions |
EP3432856A1 (en) | 2016-03-24 | 2019-01-30 | The Procter and Gamble Company | Hair care compositions comprising malodor reduction compositions |
JP2019518440A (en) | 2016-05-03 | 2019-07-04 | ダニスコ・ユーエス・インク | Protease variant and use thereof |
US20190136218A1 (en) | 2016-05-05 | 2019-05-09 | Danisco Us Inc | Protease variants and uses thereof |
MX2018014768A (en) | 2016-05-31 | 2019-03-06 | Danisco Us Inc | Protease variants and uses thereof. |
EP4151726A1 (en) | 2016-06-17 | 2023-03-22 | Danisco US Inc | Protease variants and uses thereof |
EP4357453A2 (en) | 2016-07-18 | 2024-04-24 | Novozymes A/S | Lipase variants, polynucleotides encoding same and the use thereof |
US20180119056A1 (en) | 2016-11-03 | 2018-05-03 | Milliken & Company | Leuco Triphenylmethane Colorants As Bluing Agents in Laundry Care Compositions |
US10577571B2 (en) | 2016-11-08 | 2020-03-03 | Ecolab Usa Inc. | Non-aqueous cleaner for vegetable oil soils |
US20200392477A1 (en) | 2016-12-21 | 2020-12-17 | Danisco Us Inc. | Protease variants and uses thereof |
WO2018118950A1 (en) | 2016-12-21 | 2018-06-28 | Danisco Us Inc. | Bacillus gibsonii-clade serine proteases |
EP3583210B1 (en) | 2017-03-15 | 2021-07-07 | Danisco US Inc. | Trypsin-like serine proteases and uses thereof |
EP3619304A1 (en) | 2017-05-05 | 2020-03-11 | Novozymes A/S | Compositions comprising lipase and sulfite |
CA3073362A1 (en) | 2017-09-27 | 2019-04-04 | Novozymes A/S | Lipase variants and microcapsule compositions comprising such lipase variants |
WO2019074993A1 (en) | 2017-10-10 | 2019-04-18 | The Procter & Gamble Company | Sulfate free clear personal cleansing composition comprising low inorganic salt |
CN111373039A (en) | 2017-11-29 | 2020-07-03 | 丹尼斯科美国公司 | Subtilisin variants having improved stability |
EP3720954A1 (en) | 2017-12-04 | 2020-10-14 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
JP2021505167A (en) | 2017-12-08 | 2021-02-18 | ノボザイムス アクティーゼルスカブ | α-Amylase mutant and the polynucleotide encoding it |
US10792384B2 (en) | 2017-12-15 | 2020-10-06 | The Procter & Gamble Company | Rolled fibrous structures comprising encapsulated malodor reduction compositions |
CN111868239A (en) | 2018-02-08 | 2020-10-30 | 诺维信公司 | Lipase, lipase variants and compositions thereof |
WO2019154954A1 (en) | 2018-02-08 | 2019-08-15 | Novozymes A/S | Lipase variants and compositions thereof |
US20210214703A1 (en) | 2018-06-19 | 2021-07-15 | Danisco Us Inc | Subtilisin variants |
US20210363470A1 (en) | 2018-06-19 | 2021-11-25 | Danisco Us Inc | Subtilisin variants |
EP3833731A1 (en) | 2018-08-30 | 2021-06-16 | Danisco US Inc. | Compositions comprising a lipolytic enzyme variant and methods of use thereof |
WO2020068486A1 (en) | 2018-09-27 | 2020-04-02 | Danisco Us Inc | Compositions for medical instrument cleaning |
US11732218B2 (en) | 2018-10-18 | 2023-08-22 | Milliken & Company | Polyethyleneimine compounds containing N-halamine and derivatives thereof |
US20200123472A1 (en) | 2018-10-18 | 2020-04-23 | Milliken & Company | Polyethyleneimine compounds containing n-halamine and derivatives thereof |
US20200123475A1 (en) | 2018-10-18 | 2020-04-23 | Milliken & Company | Polyethyleneimine compounds containing n-halamine and derivatives thereof |
US11466122B2 (en) | 2018-10-18 | 2022-10-11 | Milliken & Company | Polyethyleneimine compounds containing N-halamine and derivatives thereof |
US11518963B2 (en) | 2018-10-18 | 2022-12-06 | Milliken & Company | Polyethyleneimine compounds containing N-halamine and derivatives thereof |
US11299591B2 (en) | 2018-10-18 | 2022-04-12 | Milliken & Company | Polyethyleneimine compounds containing N-halamine and derivatives thereof |
US20200123319A1 (en) | 2018-10-18 | 2020-04-23 | Milliken & Company | Polyethyleneimine compounds containing n-halamine and derivatives thereof |
WO2020112599A1 (en) | 2018-11-28 | 2020-06-04 | Danisco Us Inc | Subtilisin variants having improved stability |
CN114174504A (en) | 2019-05-24 | 2022-03-11 | 丹尼斯科美国公司 | Subtilisin variants and methods of use |
WO2021001400A1 (en) | 2019-07-02 | 2021-01-07 | Novozymes A/S | Lipase variants and compositions thereof |
US11873465B2 (en) | 2019-08-14 | 2024-01-16 | Ecolab Usa Inc. | Methods of cleaning and soil release of highly oil absorbing substrates employing optimized extended chain nonionic surfactants |
EP4022020A1 (en) | 2019-08-27 | 2022-07-06 | Novozymes A/S | Composition comprising a lipase |
WO2021146255A1 (en) | 2020-01-13 | 2021-07-22 | Danisco Us Inc | Compositions comprising a lipolytic enzyme variant and methods of use thereof |
JP2023515118A (en) | 2020-02-27 | 2023-04-12 | ザ プロクター アンド ギャンブル カンパニー | Sulfur-containing antidandruff compositions with enhanced efficacy and aesthetics |
US11718814B2 (en) | 2020-03-02 | 2023-08-08 | Milliken & Company | Composition comprising hueing agent |
US20210269747A1 (en) | 2020-03-02 | 2021-09-02 | Milliken & Company | Composition Comprising Hueing Agent |
US20210277335A1 (en) | 2020-03-02 | 2021-09-09 | Milliken & Company | Composition Comprising Hueing Agent |
CN116075583A (en) | 2020-07-06 | 2023-05-05 | 埃科莱布美国股份有限公司 | Foaming mixed alcohol/water composition comprising a combination of an alkylsiloxane and a hydrotrope/solubilizer |
EP4176031A1 (en) | 2020-07-06 | 2023-05-10 | Ecolab USA Inc. | Peg-modified castor oil based compositions for microemulsifying and removing multiple oily soils |
EP4175471A1 (en) | 2020-07-06 | 2023-05-10 | Ecolab USA Inc. | Foaming mixed alcohol/water compositions comprising a structured alkoxylated siloxane |
EP4237552A2 (en) | 2020-10-29 | 2023-09-06 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
US20230407209A1 (en) | 2020-11-13 | 2023-12-21 | Novozymes A/S | Detergent Composition Comprising a Lipase |
US11819474B2 (en) | 2020-12-04 | 2023-11-21 | The Procter & Gamble Company | Hair care compositions comprising malodor reduction materials |
WO2022197295A1 (en) | 2021-03-17 | 2022-09-22 | Milliken & Company | Polymeric colorants with reduced staining |
US20220378684A1 (en) | 2021-05-14 | 2022-12-01 | The Procter & Gamble Company | Shampoo Compositions Containing a Sulfate-Free Surfactant System and Sclerotium Gum Thickener |
WO2023039270A2 (en) | 2021-09-13 | 2023-03-16 | Danisco Us Inc. | Bioactive-containing granules |
WO2023114939A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
WO2023114936A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
WO2023114932A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
WO2023116569A1 (en) | 2021-12-21 | 2023-06-29 | Novozymes A/S | Composition comprising a lipase and a booster |
WO2023247664A2 (en) | 2022-06-24 | 2023-12-28 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
US20240026248A1 (en) | 2022-07-20 | 2024-01-25 | Ecolab Usa Inc. | Novel nonionic extended surfactants, compositions and methods of use thereof |
WO2024050339A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Mannanase variants and methods of use |
WO2024050343A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Subtilisin variants and methods related thereto |
WO2024050346A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Detergent compositions and methods related thereto |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2448261A1 (en) * | 1997-03-07 | 1998-09-11 | The Procter & Gamble Company | Improved methods of making cross-bridged macropolycycles |
ZA981883B (en) * | 1997-03-07 | 1998-09-01 | Univ Kansas | Catalysts and methods for catalytic oxidation |
-
1999
- 1999-11-18 AU AU20261/00A patent/AU2026100A/en not_active Abandoned
- 1999-11-18 JP JP2000585243A patent/JP2002531457A/en not_active Withdrawn
- 1999-11-18 CA CA002348893A patent/CA2348893A1/en not_active Abandoned
- 1999-11-18 EP EP99963923A patent/EP1135392A2/en not_active Ceased
- 1999-11-18 WO PCT/US1999/027316 patent/WO2000032601A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2002531457A (en) | 2002-09-24 |
EP1135392A2 (en) | 2001-09-26 |
WO2000032601A3 (en) | 2000-10-05 |
WO2000032601A2 (en) | 2000-06-08 |
AU2026100A (en) | 2000-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2348893A1 (en) | Process for preparing cross-bridged tetraaza macrocycles | |
CA2448261A1 (en) | Improved methods of making cross-bridged macropolycycles | |
WO1994000439A1 (en) | Synthesis of 1,4,7-triazacyclononane derivatives | |
EP0034480A2 (en) | Alkylation of amines | |
EP0408340B1 (en) | Ruthenium-optically active phoshine complex useful as catalyst | |
CA2544950A1 (en) | Method for the catalytic production of hydrocodone and hydromorphone | |
WO2006103756A1 (en) | Process for production of optically active quinuclidinol | |
US7321038B2 (en) | Method for the catalytic production of hydrocodone and hydromorphone | |
WO2005047291A9 (en) | Method for the catalytic production of hydrocodone and hydromorphone | |
US5159093A (en) | Iridium-optically active phosphine complex and process for producing optically active alcohols using the same | |
MX2007011752A (en) | Method for the catalytic production of hydrocodone, hydromorphone, and derivatives thereof. | |
CN103540625A (en) | Process for the enzymatic synthesis of (7s)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) n-methyl methanamine, and application in the synthesis of ivabradine and salts thereof | |
EP0466405A1 (en) | 2,2'-Bis(dicyclopenthylphosphino)-1-1'-binaphthyl and metal complexes thereof | |
WO2009116883A2 (en) | Catalytic asymetric hydrogenation | |
EP1129095A1 (en) | Process for preparing cross-bridged tetraaza macrocycles | |
US4076724A (en) | Polycyclic macrocyclic compounds | |
AU712906B2 (en) | Preparation of substituted aromatic amines | |
US5925790A (en) | Preparation of substituted aromatic amines | |
JP4070444B2 (en) | Process for producing unsaturated amines | |
JP3930922B2 (en) | Dehalogenation method for halogen-substituted arylalkylamines | |
CN100424059C (en) | Enantiomerically enriched 2-butanol | |
CA2250850C (en) | Preparation of substituted aromatic amines | |
US6229035B1 (en) | Preparation of substituted aromatic amines | |
US5210332A (en) | Iridium-optically active phosphine complex and process for producing optically active alcohols using the same | |
CN1144795A (en) | Process for preparing chloronitrobenzene acetic acid alkyl ester |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |